ranitidin pliva 300 mg tabletti, kalvopäällysteinen
pliva pharma nordic a/s - ranitidini hydrochloridum - tabletti, kalvopäällysteinen - 300 mg - ranitidiini
azacitidine celgene
celgene europe bv - atsakitidiini - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiset aineet - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
ranixal 150 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - ranitidini hydrochloridum - tabletti, kalvopäällysteinen - 150 mg - ranitidiini
ranixal 300 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - ranitidini hydrochloridum - tabletti, kalvopäällysteinen - 300 mg - ranitidiini
zantac 150 mg tabletti, kalvopäällysteinen
glaxosmithkline (ireland) limited - ranitidini hydrochloridum - tabletti, kalvopäällysteinen - 150 mg - ranitidiini
zantac 300 mg tabletti, kalvopäällysteinen
glaxosmithkline (ireland) limited - ranitidini hydrochloridum - tabletti, kalvopäällysteinen - 300 mg - ranitidiini
zantac 15 mg/ml oraaliliuos
glaxosmithkline (ireland) limited - ranitidini hydrochloridum - oraaliliuos - 15 mg/ml - ranitidiini
inside brus 150 mg poretabletti
meda otc - ranitidini hydrochloridum - poretabletti - 150 mg - ranitidiini
inside 150 mg tabletti, kalvopäällysteinen
meda otc - ranitidini hydrochloridum - tabletti, kalvopäällysteinen - 150 mg - ranitidiini
ranisan 150 mg tabletti, kalvopäällysteinen
sandoz a/s sandoz a/s - ranitidini hydrochloridum - tabletti, kalvopäällysteinen - 150 mg - ranitidiini